Home Page
09:21:54 EDT Sat 23 Aug 2014
Enter Symbol
or Name
USA
CA



XENOPORT INC
Symbol U : XNPT
Recent Sedar Documents

XenoPort to Present at Upcoming Healthcare Conferences

2013-02-19 19:31 ET - News Release


SANTA CLARA, Calif. -- (Business Wire)

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentations at the RBC and Citigroup 2013 Healthcare Conferences. The live presentations will occur at the following dates and times:

RBC Capital Markets Healthcare Conference February 26 4:05 pm EST

Citi Global Healthcare Conference February 27 9:35 am EST

To access the live presentations via the Web, please go to www.XenoPort.com. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.

A replay of each of the Webcasts can be accessed for a minimum of one month and will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved in the United States for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia in adults. GlaxoSmithKline holds commercialization rights for Horizant in the United States during a transition period ending on April 30, 2013, following which XenoPort will be responsible for the further development, manufacturing and commercialization of Horizant. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and is being marketed for the treatment of RLS in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort’s pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson’s disease and relapsing-remitting multiple sclerosis. To learn more about XenoPort, please visit the Website at www.XenoPort.com.

Horizant,Regnite and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2G

Contacts:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com

Source: XenoPort, Inc.

© 2014 Canjex Publishing Ltd. All rights reserved.